Cantor Fitzgerald’s Arcus Biosciences RCUS Stock Holding History

Cantor Fitzgerald’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-45,000	Closed	-$972K	–	355
2026 Q1	$972K	Buy	+45,000	New	+$972K	0.01%	178

Other funds holding RCUS

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Cantor Fitzgerald's RCUS Position: Q2 2026 in Review

Cantor Fitzgerald sold out of Arcus Biosciences (RCUS) in Q2 2026, closing a stake of 45,000 shares — an estimated $972K sold.

Cantor Fitzgerald first reported a position in RCUS in Q1 2026 and held it in 1 quarter. The position peaked at $972K in Q1 2026. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

Cantor Fitzgerald reported no remaining Arcus Biosciences position as of Q2 2026 after selling out during the quarter.
Cantor Fitzgerald sold 45,000 Arcus Biosciences shares in Q2 2026, an estimated $972K.
Cantor Fitzgerald first reported a position in Arcus Biosciences in Q1 2026 and held it in 1 quarter.
Cantor Fitzgerald's Arcus Biosciences position peaked at $972K in Q1 2026.
231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Cantor Fitzgerald's 13F filing for Q2 2026, filed 14 Aug 2026.